1. Home
  2. ANGI vs DNTH Comparison

ANGI vs DNTH Comparison

Compare ANGI & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANGI
  • DNTH
  • Stock Information
  • Founded
  • ANGI 1995
  • DNTH 2015
  • Country
  • ANGI United States
  • DNTH United States
  • Employees
  • ANGI N/A
  • DNTH N/A
  • Industry
  • ANGI Advertising
  • DNTH Biotechnology: Pharmaceutical Preparations
  • Sector
  • ANGI Consumer Discretionary
  • DNTH Health Care
  • Exchange
  • ANGI Nasdaq
  • DNTH Nasdaq
  • Market Cap
  • ANGI 823.0M
  • DNTH 606.2M
  • IPO Year
  • ANGI 2017
  • DNTH N/A
  • Fundamental
  • Price
  • ANGI $16.01
  • DNTH $20.80
  • Analyst Decision
  • ANGI Hold
  • DNTH Strong Buy
  • Analyst Count
  • ANGI 8
  • DNTH 8
  • Target Price
  • ANGI $20.33
  • DNTH $53.00
  • AVG Volume (30 Days)
  • ANGI 639.2K
  • DNTH 373.9K
  • Earning Date
  • ANGI 08-05-2025
  • DNTH 08-07-2025
  • Dividend Yield
  • ANGI N/A
  • DNTH N/A
  • EPS Growth
  • ANGI N/A
  • DNTH N/A
  • EPS
  • ANGI 1.03
  • DNTH N/A
  • Revenue
  • ANGI $1,125,635,000.00
  • DNTH $6,524,000.00
  • Revenue This Year
  • ANGI N/A
  • DNTH N/A
  • Revenue Next Year
  • ANGI $3.67
  • DNTH N/A
  • P/E Ratio
  • ANGI $15.56
  • DNTH N/A
  • Revenue Growth
  • ANGI N/A
  • DNTH 102.36
  • 52 Week Low
  • ANGI $10.88
  • DNTH $13.37
  • 52 Week High
  • ANGI $29.15
  • DNTH $32.27
  • Technical
  • Relative Strength Index (RSI)
  • ANGI 47.32
  • DNTH 54.23
  • Support Level
  • ANGI $15.94
  • DNTH $21.27
  • Resistance Level
  • ANGI $17.19
  • DNTH $23.21
  • Average True Range (ATR)
  • ANGI 0.56
  • DNTH 1.19
  • MACD
  • ANGI -0.06
  • DNTH 0.07
  • Stochastic Oscillator
  • ANGI 15.11
  • DNTH 44.60

About ANGI Angi Inc.

Angi Inc connects quality home service professionals with consumers across different categories, from repairing and remodeling to cleaning and landscaping. It operates through brands like Angi, HomeAdvisor, and Handy. The company has three operating segments, namely, Ads and Leads, Services, and International (Europe and Canada). A majority of its revenue is generated from the Ads and Leads segment, which provides professionals the capability to engage with potential customers, including quoting and invoicing services, and provides consumers with tools and resources to help them find professionals nationwide for home repair, maintenance, and improvement projects. Geographically, the company derives its key revenue from the United States and also has a presence in other countries.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Share on Social Networks: